Calithera begins Phase II trial of CB-839 to treat renal cell carcinoma
Pharmaceutical firm Calithera Biosciences has begun a Phase II clinical trial of CB-839 in combination with Afinitor (everolimus) for the treatment of patients with renal cell carcinoma (RCC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Pharmaceuticals | Renal Cell Carcinoma